October 12, 2020 - Singapore News Tribe

Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

La Chaux-de-Fonds, Switzerland and Shanghai, China. October 12, 2020, Oct. 12, 2020 (GLOBE NEWSWIRE) — Rhizen …

An icebreaker belonging to Germany’s Alfred Wegener Institute (AWI) returned to Germany Monday with what the scienti…

The head of the World Health Organization is warning against a strategy of pursuing herd immunity to stop the coronavir…

TAIPEI, TAIWAN – Newly appointed Japanese Prime Minister Yoshihide Suga plans to visit Southeast Asia this mon…